Accessory cells, cytokine loops and cell-to-cell interactions in chronic lymphocytic leukemia

Reviews in Clinical and Experimental Hematology

Volumn 4, Issue 1, 2000, Pages 73-98

  Orsini, Enrica ^a   Guarini, Anna ^a   Foa, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

CANCER IMMUNOLOGY; CELL INTERACTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; MOLECULAR INTERACTION; REVIEW; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; CELL COMMUNICATION; CLONE CELLS; CYTOKINES; HUMANS; LEUKEMIA, B-CELL, CHRONIC;

EID: 0034160359     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2000.00004.x     Document Type: Review

References (146)

1. Pathogenesis of the immunodeficiency in B-cell chronic lymphocytic leukemia
2. Impairments in immune cell function in B cell chronic lymphocytic leukemia
3. Chronic lymphocytic leukemia: Clinical studies based on 189 cases followed for a long time
4. Chronic lymphocytic leukemia
5. Clinical significance of T cells in chronic lymphocytic leukaemia
6. Clinical staging and immunological findings in chronic lymphocytic leukemia
7. T-cell subpopulations in chronic lymphocytic leukemia: Abnormalities in distribution and in vitro maturation
8. Increase in Tγ lymphocytes in B-cell chronic lymphocytic leukaemia
9. Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia. An analysis by monoclonal antibodies
10. T lymphocytes in B-cell chronic lymphocytic leukemia: Characterization by monoclonal antibodies and correlation with Fc receptors
11. T cells and CD45R expression in B-chronic lymphocytic leukemia
12. Immunophenotypic and DNA genotypic analysis of T-cell and NK-cell subpopulations in patients with B-cell chronic lymphocytic leukaemia (B-CLL)
13. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease
14. Decreased CD45RA T cells in B-cell chronic lymphatic leukemia patients: Correlation with disease stage
15. Selective loss of the suppressor-inducer T cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody
16. T cell helper defect in patients with chronic lymphocytic leukemia
17. T cell functional abnormality in B-chronic lymphocytic leukaemia: Evidence of a defect of the T-helper subset
18. Defective helper function of purified T4 dells and excessive suppressor activity of purified T8 cells in patients with B-cell chronic lymphocytic leukemia. T4 suppressor effector cells are present in certain patients
19. Function of lymphocyte subpopulations in chronic lymphocytic leukemia. Activity in the allogeneic and autologous mixed lymphocyte reaction
20. Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals
21. Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: Correlation with disease status and neoplastic phenotype
22. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia
23. lck in T-cells infiltrating human renal cell carcinoma
24. Decreased expression of the signaltransducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma
25. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance
26. - cells
27. T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions
28. + T cell subsets in chronic lymphocytic leukemia
29. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: Major perturbations are preferentially seen within the CD4 T-cell subset
30. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human mouse radiation chimera
31. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocytes induction by up-regulation of CD80 and CD86 costimulatory molecules
32. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells
33. CD154 (CD40-ligand) gene immunization of CLL patients leads to amnestic T cell responses
34. Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: Results of a pilot study
35. Reduced natural killer T-cells in B-cell chronic lymphocytic leukaemia identified by three monoclonal antibodies. Leu-11, A10, AB8.28
36. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia
37. Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocytic leukemia
38. Immunoregulatory cell dysfunction in chronic B-cell leukemias
39. Prognostic significance of immune function parameters in patients with chronic lymphocytic leukaemia
40. Defective spontaneous and antibodydependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: Augmentation by in vitro treatment with interferon
41. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia
42. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells
43. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: Defective LAK generation and reduced susceptibility of the leukemic cells to autologous and allogeneic LAK effectors
44. Evidence that large granular lymphocytes from B-CLL patients with hypogammaglobulinemia downregulate B-cell immunoglobulin synthesis
45. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells
46. Production of cytokines by human B cells in health and disease
47. The IL-2 receptor complex: Expression and function on normal and leukemic B cells
48. Interleukin 2 (IL2) and interferon-γ production by T lymphocytes from patients with B-chronic lymphocytic leukemia: Evidence that normally released IL2 is absorbed by the neoplastic B cell population
49. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia
50. The released interleukin 2 receptor binds interleukin 2 efficiently
51. Defective interleukin-2 production and responsiveness by T cells in patients with chronic lymphocytic leukemia of B cell variety
52. Immunoregulatory T-cell defects in B-cell chronic lymphocytic leukemia: Cause or consequence of the disease? The contributory role of a decreased availability of interleukin 2 (IL2)
53. Lymphokine induction of NK-like cytotoxicity in T cells from B-CLL
54. Interleukin 2-induced proliferation of leukemic human B cells
55. Autocrine and paracrine models of cytokine production and utilization in B-cell chronic lymphocytic leukaemia
56. Tumour necrosis factor
57. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies
58. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease
59. Serum levels of tumour necrosis factor-alpha in patients with B-cell chronic lymphocytic leukaemia
60. Cytokine expression in B-CLL in relation to disease progression and in vitro activation
61. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia
62. Proliferative response of highly purified B chronic lymphocytic leukemia cells in serum free culture to interleukin-2 and tumor necrosis factors alpha and beta
63. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia
64. Heterogeneous proliferative effect of tumor necrosis factor-alpha and lymphotoxin on mitogen-activated B cells from B-chronic lymphocytic leukemia
65. The effect of cytokines on cultured mononuclear cells from patients with B cell chronic lymphocytic leukemia
66. Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo
67. TNF receptors in chronic lymphocytic leukemia
68. Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy
69. Serum levels of TNF-α and IL-6 in B-CLL patients with anemia
70. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils
71. Leukocyte specificity and binding of human neutrophil attractant/activation protein-1
72. Interleukin 8 MCAF: Novel inflammatory cytokines inducible by IL 1 and TNF
73. Human neutrophils exhibit disparate chemotactic factor gene expression
74. Cytokine gene expression in B-cell chronic lymphocytic leukemia: Evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein
75. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion
76. Clinicobiological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia
77. Identification of a T cell-derived B cell growth factor distinct from interleukin 2
78. Interleukin 4 counteracts the interleukin 2-induced proliferation of monoclonal B cells
79. Dual effects of interleukin 4 on antigen-activated human B cells: Induction of proliferation and inhibition of interleukin 2-dependent differentiation
80. Expression of IL-4 receptor on human T and B lymphocytes
81. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors
82. Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alphainduced proliferation of B chronic lymphocytic leukemia cells
83. Interleukin-4 (IL-4) inhibits proliferation and spontaneous cytokine release by chronic lymphocytic leukaemia cells
84. Analysis of signal transduction in B chronic lymphocytic leukemia cells
85. Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositol-specific phospholipase C
86. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression
87. Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4
88. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: Evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells
89. + T-cell subset in B-cell chronic lymphocytic leukaemia
90. Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients
91. Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells
92. Interleukin-4 prevents spontaneous in-vitro apoptosis in chronic lymphatic leukaemia but sensitises B-CLL cells to melphalan cytotoxicity
93. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI
94. Role of IL-10 in cross-regulation of Th1 and Th2 responses
95. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
96. Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease
97. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells
98. Serum levels of interleukin-10 in B-cell chronic lymphocytic leukemia
99. IL-10 serum levels in B-cell chronic lymphocytic leukaemia
100. Serum levels of tetranectin, intercellular adhesion molecule-1 and interleukin-10 in B-chronic lymphocytic leukemia
101. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein
102. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10
103. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells
104. Interferon-alpha up-regulates bcl-2 expression and protects B-CLL from apoptosis in vitro and in vivo
105. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia
106. Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia
107. Resistance of rheumatoid synovial dendritic cells to the immunosuppressive effects of IL-10
108. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function
109. + T cell clones in human immunodeficiency virus infection
110. + T cells producing Th2-type cytokines
111. + T cells by IL-4 and IFN-gamma
112. CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals
113. Human Tc1 and Tc2/Tc0, CD8 T-cell clones display distinct cell surface and functional phenotypes
114. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin
115. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules
116. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas
117. Mechanism of antigen-driven selection in germinal centres
118. T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death
119. Human B cell precursors proliferate and express CD23 after CD40 ligation
120. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells
121. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40)
122. Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes
123. + T cells that induces contactdependent B cell differentiation (help)
124. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome
125. Acquired CD40-ligand deficiency in chronic lymphocytic leukaemia
126. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity
127. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells
128. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia
129. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells
130. Gene therapy for CLL
131. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor
132. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
133. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
134. Clinical, immunological, and pathological consequences of Fas-deficient conditions
135. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia
136. Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias
137. Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms
138. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias
139. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl-2 oncogene expression
140. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies
141. Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants
142. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells
143. Effect of anti-APO1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: The role of bcl-2 and interleukin 4
144. Fas-mediated lysis of chronic lymphocytic leukaemia cells: Role of type I versus type II cytokines and autologous FasL-expressing T cells
145. + tumor cells in B chronic lymphocytic leukemia